Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | MSH2 |
| Variant | E580* |
| Impact List | nonsense |
| Protein Effect | loss of function - predicted |
| Gene Variant Descriptions | MSH2 E580* results in a premature truncation of the Msh2 protein at amino acid 580 of 934 (UniProt.org). E580* has not been characterized however, due to the loss of the ATPase domain (PMID: 17531815, PMID: 23391514), is predicted to lead to a loss of Msh2 protein function. |
| Associated Drug Resistance | |
| Category Variants Paths |
MSH2 mutant MSH2 inact mut MSH2 E580* |
| Transcript | NM_000251.3 |
| gDNA | chr2:g.47471041G>T |
| cDNA | c.1738G>T |
| Protein | p.E580* |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_001406633.1 | chr2:g.47471041G>T | c.1738G>T | p.E580* | RefSeq | GRCh38/hg38 |
| NM_001406639.1 | chr2:g.47471041G>T | c.1738G>T | p.E580* | RefSeq | GRCh38/hg38 |
| NM_001406646.1 | chr2:g.47471041G>T | c.1738G>T | p.E580* | RefSeq | GRCh38/hg38 |
| XM_011532867 | chr2:g.47471041G>T | c.1738G>T | p.E580* | RefSeq | GRCh38/hg38 |
| NM_001406648.1 | chr2:g.47471041G>T | c.1738G>T | p.E580* | RefSeq | GRCh38/hg38 |
| NM_001406631.1 | chr2:g.47471041G>T | c.1738G>T | p.E580* | RefSeq | GRCh38/hg38 |
| NM_001406643.1 | chr2:g.47471041G>T | c.1738G>T | p.E580* | RefSeq | GRCh38/hg38 |
| XM_005264332 | chr2:g.47471041G>T | c.1738G>T | p.E580* | RefSeq | GRCh38/hg38 |
| NM_001406634.1 | chr2:g.47471041G>T | c.1738G>T | p.E580* | RefSeq | GRCh38/hg38 |
| NM_001406635.1 | chr2:g.47471041G>T | c.1738G>T | p.E580* | RefSeq | GRCh38/hg38 |
| NM_001406645.1 | chr2:g.47471041G>T | c.1738G>T | p.E580* | RefSeq | GRCh38/hg38 |
| NM_000251.3 | chr2:g.47471041G>T | c.1738G>T | p.E580* | RefSeq | GRCh38/hg38 |
| NM_001406641.1 | chr2:g.47471041G>T | c.1738G>T | p.E580* | RefSeq | GRCh38/hg38 |
| XM_011532867.2 | chr2:g.47471041G>T | c.1738G>T | p.E580* | RefSeq | GRCh38/hg38 |
| NM_001406655.1 | chr2:g.47471041G>T | c.1738G>T | p.E580* | RefSeq | GRCh38/hg38 |
| XM_047444416.1 | chr2:g.47471041G>T | c.1738G>T | p.E580* | RefSeq | GRCh38/hg38 |
| XM_005264332.4 | chr2:g.47471041G>T | c.1738G>T | p.E580* | RefSeq | GRCh38/hg38 |
| NM_001406632.1 | chr2:g.47471041G>T | c.1738G>T | p.E580* | RefSeq | GRCh38/hg38 |
| NM_001406642.1 | chr2:g.47471041G>T | c.1738G>T | p.E580* | RefSeq | GRCh38/hg38 |
| NM_001406674.1 | chr2:g.47471041G>T | c.1738G>T | p.E580* | RefSeq | GRCh38/hg38 |
| NM_001406640.1 | chr2:g.47471041G>T | c.1738G>T | p.E580* | RefSeq | GRCh38/hg38 |
| NM_001406637.1 | chr2:g.47471041G>T | c.1738G>T | p.E580* | RefSeq | GRCh38/hg38 |
| NM_000251.2 | chr2:g.47471041G>T | c.1738G>T | p.E580* | RefSeq | GRCh38/hg38 |
| NM_001406644.1 | chr2:g.47471041G>T | c.1738G>T | p.E580* | RefSeq | GRCh38/hg38 |
| NM_000251 | chr2:g.47471041G>T | c.1738G>T | p.E580* | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MSH2 inact mut | endometrial adenocarcinoma | sensitive | Baicalein | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Baicalein selectively induced cell death in an endometrial adenocarcinoma cell line with MSH2 inactivation in culture, and induced apoptosis and tumor shrinkage in MSH2-deficient endometrial adenocarcinoma cell line xenograft models (PMID: 27262172). | 27262172 |
| MSH2 inact mut | colon cancer | sensitive | Baicalein | Preclinical | Actionable | In a preclinical study, treatment with Baicalein resulted in decreased growth of azoxymethane/dextran sodium sulfate-induced colon tumors in a MSH2-deficient mouse model (PMID: 27262172). | 27262172 |
| MSH2 mutant | small intestine adenocarcinoma | not applicable | N/A | Guideline | Risk Factor | Lynch syndrome results from germline mutations in DNA mismatch repair genes including MLH1, MSH2, MSH6, and PMS2, and is associated with increased risk of developing small bowel adenocarcinoma (NCCN.org). | detail... |
| MSH2 mutant | endometrial carcinoma | not applicable | N/A | Guideline | Risk Factor | Germline mutations in MSH2 result in Lynch syndrome, which is associated with increased risk of developing endometrial carcinoma (NCCN.org). | detail... |
| MSH2 mutant | rectum cancer | not applicable | N/A | Guideline | Risk Factor | Lynch syndrome results from germline mutations in DNA mismatch repair genes including MLH1, MSH2, MSH6, and PMS2, and is associated with increased risk of developing colorectal cancer (NCCN.org). | detail... |
| MSH2 mutant | pancreatic cancer | not applicable | N/A | Guideline | Risk Factor | Germline mutations in MSH2 result in Lynch syndrome, which is associated with increased risk of developing pancreatic cancer (NCCN.org). | detail... |
| MSH2 mutant | stomach cancer | not applicable | N/A | Guideline | Risk Factor | Germline mutations in MSH2 result in Lynch syndrome, which is associated with increased risk of early onset of gastric cancer (NCCN.org). | detail... |
| MSH2 mutant | colon cancer | not applicable | N/A | Guideline | Risk Factor | Lynch syndrome results from germline mutations in DNA mismatch repair genes including MLH1, MSH2, MSH6, and PMS2, and is associated with increased risk of developing colon cancer (NCCN.org). | detail... |
| MSH2 mutant | ovarian cancer | not applicable | N/A | Guideline | Risk Factor | Germline mutations in MSH2 result in Lynch syndrome, which is associated with increased risk of ovarian cancer (NCCN.org). | detail... |
| MSH2 mutant | adrenocortical carcinoma | not applicable | N/A | Guideline | Risk Factor | Lynch syndrome results from germline mutations in DNA mismatch repair genes including MLH1, MSH2, MSH6, and PMS2, and is associated with increased risk of developing adrenocortical carcinoma (NCCN.org). | detail... |